Sakai Takashi, Aokage Keiju, Miyoshi Tomohiro, Tane Kenta, Ishii Genichiro, Goto Koichi, Tsuboi Masahiro
Department of Thoracic Surgery, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Division of Chest Surgery, Department of Surgery, Toho University School of Medicine, Ota, Tokyo, Japan.
Surg Today. 2023 Jan;53(1):42-50. doi: 10.1007/s00595-022-02530-7. Epub 2022 Jul 30.
This study investigated the prognostic factors of thymic epithelial tumors (TETs) to identify patients who require multidisciplinary treatment and improve the TET prognosis.
We retrospectively reviewed the data of 268 TET patients. Prognostic variables for the overall survival (OS) were analyzed in all TET stages (n = 268), and the recurrence-free survival (RFS) was analyzed in patients who achieved complete resection (n = 164).
The median follow-up period was 7 years; thymic carcinomas (TCs) and advanced stages of tumor, node, and metastasis (TNM) classification had the worse prognosis according to a Kaplan-Meier analysis. The cut-off value of the tumor size to predict the OS and RFS was determined using modified Harrell's c-index calculated by a Cox regression analysis of the OS. Regarding the OS, a multivariate analysis revealed that age > 70 years old (p = 0.011), tumor size > 5 cm (p < 0.001), and TCs (p = 0.002) were significant prognostic factors aside from the TNM stage (p < 0.001). Regarding the RFS, tumor size > 5 cm was the only significant prognostic factor in the multivariate analysis (p = 0.002) aside from the TNM stage (p = 0.008).
Tumor size > 5 cm was shown to be a prognostic predictor in addition to the WHO and TNM classifications. Therefore, multidisciplinary treatment should be developed for TET patients with poor prognostic factors, specifically tumor size.
本研究调查胸腺上皮肿瘤(TETs)的预后因素,以识别需要多学科治疗的患者并改善TETs的预后。
我们回顾性分析了268例TET患者的数据。对所有TET分期(n = 268)的总生存期(OS)的预后变量进行分析,对实现完全切除的患者(n = 164)分析无复发生存期(RFS)。
中位随访期为7年;根据Kaplan-Meier分析,胸腺癌(TCs)以及肿瘤、淋巴结和转移(TNM)分期的晚期预后较差。通过对OS进行Cox回归分析计算修正的Harrell's c指数,确定预测OS和RFS的肿瘤大小临界值。关于OS,多变量分析显示,除TNM分期(p < 0.001)外,年龄> 70岁(p = 0.011)、肿瘤大小> 5 cm(p < 0.001)和TCs(p = 0.002)是显著的预后因素。关于RFS,除TNM分期(p = 0.008)外,肿瘤大小> 5 cm是多变量分析中唯一显著的预后因素(p = 0.002)。
除了世界卫生组织(WHO)和TNM分类外,肿瘤大小> 5 cm被证明是一个预后预测指标。因此,应针对具有不良预后因素,特别是肿瘤大小的TET患者制定多学科治疗方案。